What's Happening?
Researchers have developed a drug screening platform that targets the primary cause of neurological and psychiatric disorders: protein expression levels. The platform uses the Protein Quantitation Ratioing (PQR) technique to monitor protein expression in human
cell lines, employing CRISPR-Cas9 genome editing to insert the Protein Quantitation Reporter into target genes. This allows for high-throughput drug screening, measuring fluorescence as an assay. The platform aims to identify compounds that can correct protein synthesis malfunctions, which are responsible for many neurological conditions affecting over half the population.
Why It's Important?
The development of this drug screening platform could significantly impact the treatment of neurological disorders, which affect a large portion of the population. By focusing on protein expression levels, the platform offers a novel approach to identifying potential therapeutic compounds. This could lead to the discovery of new treatments for conditions that currently have limited options, improving patient outcomes and quality of life. The use of advanced techniques like CRISPR-Cas9 and high-throughput screening also highlights the role of cutting-edge technology in advancing drug discovery and development.
